RECIDA THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01
Phase 1
Terminated
- Conditions
- Safety
- Interventions
- Drug: Single intravenous doses of RC-01Drug: Multiple intravenous doses of RC-01Drug: Multiple intravenous doses of placeboDrug: Single intravenous doses of placebo
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Recida Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03832517
- Locations
- 🇺🇸
Celerion, Phoenix, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath